Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Rhea-AI Summary
Anixa (NASDAQ: ANIX) announced a presentation on its ovarian cancer CAR-T therapy, lira-cel, at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, May 6–9, 2026.
The presentation will cover the Phase 1 trial design, objectives, and the current status, with the company noting that lira-cel continues to show positive survival data in the ongoing study.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
In the Apr 22 session, ANIX gained 9.03%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Conference participation | Positive | +0.4% | Biotech conference presentation covering pipeline and positive Phase 1 data. |
| Apr 07 | Conference participation | Positive | +3.9% | Virtual conference talk on company strategy and clinical program highlights. |
| Apr 06 | Media interview | Positive | +1.6% | CEO interview emphasizing advancing immunotherapy pipeline and early results. |
| Apr 01 | Clinical trial update | Positive | +5.4% | Positive final Phase 1 breast cancer vaccine results and Phase 2 preparation. |
| Mar 30 | Clinical trial presentation | Positive | -2.0% | Ovarian CAR-T Phase 1 trial update at a gynecologic oncology meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and visibility updates have more often been followed by modest share gains, with occasional divergences on conference-style announcements.
Over the last few months, ANIX has highlighted steady progress across its immunotherapy pipeline. Updates included multiple conference and virtual presentation announcements in early April 2026 and stronger Phase 1 data for both its breast cancer vaccine and ovarian CAR-T therapy. These events generally saw small positive price reactions, especially the Apr 1 breast cancer Phase 1 update, while one ovarian CAR-T conference presentation on Mar 30 drew a slight negative move. Today’s ISCT presentation continues that pattern of scientific visibility rather than new topline data.
Key Terms
car-t medical
autologous t cells medical
chimeric receptor medical
follicle-stimulating hormone receptor (fshr) medical
gene editing medical
bioprocessing technical
clinical translation medical
cell & gene therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial
Ms. Cox's presentation, titled "Phase 1 clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer," will discuss the clinical trial design and objectives, as well as the current status of Anixa's ongoing Phase 1 clinical trial of lira-cel.
The ISCT 2026 Annual Meeting will bring together thousands of global experts in cell and gene therapy. This event is recognized as the largest conference focused on translating cell and gene therapies from research to clinical practice. The four-day program will feature hundreds of speakers, cutting edge scientific presentations, and interactive sessions covering advances in areas such as gene editing, bioprocessing, and clinical translation, alongside extensive networking opportunities and industry showcases.
About Lira-cel, Anixa's CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-of-its-ovarian-cancer-car-t-therapy-at-the-international-society-for-cell--gene-therapy-2026-annual-meeting-302749566.html
SOURCE Anixa Biosciences, Inc.